Targeting pyruvate carboxylase reduces gluconeogenesis and adiposity and improves insulin resistance

Diabetes

Volumn 62, Issue 7, 2013, Pages 2183-2194

  Kumashiro, Naoki ^a   Beddow, Sara A ^b   Vatner, Daniel F ^a   Majumdar, Sachin K ^a   Cantley, Jennifer L ^a   Guebre Egziabher, Fitsum ^a   Fat, Ioana ^a   Guigni, Blas ^a   Jurczak, Michael J ^a   Birkenfeld, Andreas L ^a   Kahn, Mario ^a   Perler, Bryce K ^a   Puchowicz, Michelle A ^c   Manchem, Vara Prasad ^d   Bhanot, Sanjay ^d   Still, Christopher D ^e   Gerhard, Glenn S ^e   Petersen, Kitt Falk ^a   Cline, Gary W ^a   Shulman, Gerald I ^a   Samuel, Varman T ^a,b   more..

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

^c CASE WESTERN RESERVE UNIVERSITY   (United States)

^d ISIS PHARMACEUTICALS   (United States)

^e WEIS CENTER FOR RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; GLUCOSE; INSULIN; MESSENGER RNA; PYRUVATE CARBOXYLASE; GLYCEROL;

ADULT; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BODY COMPOSITION; CLINICAL ARTICLE; CONTROLLED STUDY; FATTY ACID OXIDATION; FATTY ACID SYNTHESIS; FEMALE; GENE EXPRESSION; GLUCONEOGENESIS; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HUMAN; HUMAN TISSUE; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID METABOLISM; LIPOLYSIS; LIVER BIOPSY; MALE; METABOLIC PARAMETERS; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING; ADIPOSE TISSUE; ANIMAL; ENZYMOLOGY; FATTY LIVER; LIVER; METABOLISM; MIDDLE AGED; PHYSIOLOGY; SPRAGUE DAWLEY RAT; ZUCKER RAT;

ADIPOSE TISSUE; ADIPOSITY; ADULT; ANIMALS; FATTY LIVER; FEMALE; GLUCONEOGENESIS; GLYCEROL; HUMANS; INSULIN RESISTANCE; LIVER; MALE; MIDDLE AGED; PYRUVATE CARBOXYLASE; RATS; RATS, SPRAGUE-DAWLEY; RATS, ZUCKER;

EID: 84883705437     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db12-1311     Document Type: Article

References (52)

1. Magnusson I, Rothman DL, Katz LD, Shulman RG, Shulman GI. Increased rate of gluconeogenesis in type II diabetes mellitus. A 17C nuclear magnetic resonance study. J Clin Invest 1992;90:1323-1327
2. Maggs DG, Buchanan TA, Burant CF, et al. Metabolic effects of troglitazone monotherapy in type 2 diabetes mellitus. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1998;128:176-185
3. Hundal RS, Krssak M, Dufour S, et al. Mechanism by which metformin reduces glucose production in type 2 diabetes. Diabetes 2000;49:2063-2069
4. Utter MF, Keech DB. Formation of oxaloacetate from pyruvate and carbon dioxide. J Biol Chem 1960;235:PC17-PC18
5. Weber G, Cantero A. Glucose-6-phosphatase studies in fasting. Science 1954;120:851-852
6. Utter MF, Kurahashi K. Purification of oxalacetic carboxylase from chicken liver. J Biol Chem 1954;207:787-802
7. McGilvery RW, Mokrasch LC. Purification and properties of fructose-1, 6-diphosphatase. J Biol Chem 1956;221:909-917
8. Jurado LA, Song S, Roesler WJ, Park EA. Conserved amino acids within CCAAT enhancer-binding proteins (C/EBP(alpha) and beta) regulate phosphoenolpyruvate carboxykinase (PEPCK) gene expression. J Biol Chem 2002;277:27606-27612
9. Koo SH, Flechner L, Qi L, et al. The CREB coactivator TORC2 is a key regulator of fasting glucose metabolism. Nature 2005;437:1109-1111
10. Nakae J, Kitamura T, Silver DL, Accili D. The forkhead transcription factor Foxo1 (Fkhr) confers insulin sensitivity onto glucose-6-phosphatase expression. J Clin Invest 2001;108:1359-1367
11. O'Brien RM, Noisin EL, Suwanichkul A, et al. Hepatic nuclear factor 3- and hormone-regulated expression of the phosphoenolpyruvate carboxykinase and insulin-like growth factor-binding protein 1 genes. Mol Cell Biol 1995; 15:1747-1758
12. Yoon JC, Puigserver P, Chen G, et al. Control of hepatic gluconeogenesis through the transcriptional coactivator PGC-1. Nature 2001;413:131-138
13. Burgess SC, He T, Yan Z, et al. Cytosolic phosphoenolpyruvate carboxykinase does not solely control the rate of hepatic gluconeogenesis in the intact mouse liver. Cell Metab 2007;5:313-320
14. Le Lay J, Tuteja G, White P, Dhir R, Ahima R, Kaestner KH. CRTC2 (TORC2) contributes to the transcriptional response to fasting in the liver but is not required for the maintenance of glucose homeostasis. Cell Metab 2009;10:55-62
15. Ramnanan CJ, Edgerton DS, Rivera N, et al. Molecular characterization of insulin-mediated suppression of hepatic glucose production in vivo. Diabetes 2010;59:1302-1311
16. Sloop KW, Showalter AD, Cox AL, et al. Specific reduction of hepatic glucose 6-phosphate transporter-1 ameliorates diabetes while avoiding complications of glycogen storage disease. J Biol Chem 2007;282:19113-19121
17. Samuel VT, Beddow SA, Iwasaki T, et al. Fasting hyperglycemia is not associated with increased expression of PEPCK or G6Pc in patients with type 2 diabetes. Proc Natl Acad Sci U S A 2009;106:12121-12126
18. Jitrapakdee S, St Maurice M, Rayment I, Cleland WW, Wallace JC, Attwood PV. Structure, mechanism and regulation of pyruvate carboxylase. Biochem J 2008;413:369-387
19. Weinberg MB, Utter MF. Effect of streptozotocin-induced diabetes mellitus on the turnover of rat liver pyruvate carboxylase and pyruvate dehydrogenase. Biochem J 1980;188:601-608
20. Large V, Beylot M. Modifications of citric acid cycle activity and gluconeogenesis in streptozotocin-induced diabetes and effects of metformin. Diabetes 1999;48:1251-1257
21. Jitrapakdee S, Gong Q, MacDonald MJ, Wallace JC. Regulation of rat pyruvate carboxylase gene expression by alternate promoters during development, in genetically obese rats and in insulin-secreting cells. Multiple transcripts with 59-end heterogeneity modulate translation. J Biol Chem 1998;273:34422-34428
22. Bahl JJ, Matsuda M, DeFronzo RA, Bressler R. In vitro and in vivo suppression of gluconeogenesis by inhibition of pyruvate carboxylase. Biochem Pharmacol 1997;53:67-74
23. Nagai Y, Yonemitsu S, Erion DM, et al. The role of peroxisome proliferatoractivated receptor gamma coactivator-1 beta in the pathogenesis of fructose- induced insulin resistance. Cell Metab 2009;9:252-264
24. Sazani P, Gemignani F, Kang SH, et al. Systemically delivered antisense oligomers upregulate gene expression in mouse tissues. Nat Biotechnol 2002;20:1228-1233
25. Chu X, Erdman R, Susek M, et al. Association of morbid obesity with FTO and INSIG2 allelic variants. Arch Surg 2008;143:235-240; discussion 241
26. Kumashiro N, Yoshimura T, Cantley JL, et al. Role of patatin-like phospholipase domain-containing 3 on lipid-induced hepatic steatosis and insulin resistance in rats. Hepatology 2013;57:1763-1772
27. Kumashiro N, Erion DM, Zhang D, et al. Cellular mechanism of insulin resistance in nonalcoholic fatty liver disease. Proc Natl Acad Sci U S A 2011;108:16381-16385
28. Wiese TJ, Lambeth DO, Ray PD. The intracellular distribution and activities of phosphoenolpyruvate carboxykinase isozymes in various tissues of several mammals and birds. Comp Biochem Physiol B 1991;100:297-302
29. Petrescu I, Bojan O, Saied M, Bârzu O, Schmidt F, Kühnle HF. Determination of phosphoenolpyruvate carboxykinase activity with deoxyguanosine 59-diphosphate as nucleotide substrate. Anal Biochem 1979;96: 279-281
30. Kumashiro N, Tamura Y, Uchida T, et al. Impact of oxidative stress and peroxisome proliferator-activated receptor gamma coactivator-1alpha in hepatic insulin resistance. Diabetes 2008;57:2083-2091
31. Samuel VT, Liu ZX, Wang A, et al. Inhibition of protein kinase Cepsilon prevents hepatic insulin resistance in nonalcoholic fatty liver disease. J Clin Invest 2007;117:739-745
32. Birkenfeld AL, Lee HY, Guebre-Egziabher F, et al. Deletion of the mammalian INDY homolog mimics aspects of dietary restriction and protects against adiposity and insulin resistance in mice. Cell Metab 2011;14:184- 195
33. Bederman IR, Foy S, Chandramouli V, Alexander JC, Previs SF. Triglyceride synthesis in epididymal adipose tissue: contribution of glucose and non-glucose carbon sources. J Biol Chem 2009;284:6101-6108
34. Turner SM, Murphy EJ, Neese RA, et al. Measurement of TG synthesis and turnover in vivo by 2H2O incorporation into the glycerol moiety and application of MIDA. Am J Physiol Endocrinol Metab 2003;285:E790- E803
35. Samuel VT, Shulman GI. Mechanisms for insulin resistance: common threads and missing links. Cell 2012;148:852-871
36. Jitrapakdee S, Vidal-Puig A, Wallace JC. Anaplerotic roles of pyruvate carboxylase in mammalian tissues. Cell Mol Life Sci 2006;63:843-854
37. Jitrapakdee S, Slawik M, Medina-Gomez G, et al. The peroxisome proliferator- activated receptor-gamma regulates murine pyruvate carboxylase gene expression in vivo and in vitro. J Biol Chem 2005;280:27466-27476
38. Wellen KE, Uysal KT, Wiesbrock S, Yang Q, Chen H, Hotamisligil GS. Interaction of tumor necrosis factor-alpha- and thiazolidinedione-regulated pathways in obesity. Endocrinology 2004;145:2214-2220
39. Wilson-Fritch L, Nicoloro S, Chouinard M, et al. Mitochondrial remodeling in adipose tissue associated with obesity and treatment with rosiglitazone. J Clin Invest 2004;114:1281-1289
40. Cobelli C, Mari A, Duner E, Mollo F, Nosadini R. On the estimation of absorption of subcutaneous injected insulin from plasma concentrations using mathematical models. Diabetologia 1984;26:314-316
41. Woerle HJ, Szoke E, Meyer C, et al. Mechanisms for abnormal postprandial glucose metabolism in type 2 diabetes. Am J Physiol Endocrinol Metab 2006;290:E67-E77
42. Sunny NE, Parks EJ, Browning JD, Burgess SC. Excessive hepatic mitochondrial TCA cycle and gluconeogenesis in humans with nonalcoholic fatty liver disease. Cell Metab 2011;14:804-810
43. Farfari S, Schulz V, Corkey B, Prentki M. Glucose-regulated anaplerosis and cataplerosis in pancreatic beta-cells: possible implication of a pyruvate/ citrate shuttle in insulin secretion. Diabetes 2000;49:718-726
44. Jitrapakdee S, Booker GW, Cassady AI, Wallace JC. The rat pyruvate carboxylase gene structure. Alternate promoters generate multiple transcripts with the 59-end heterogeneity. J Biol Chem 1997;272:20522-20530
45. Marin-Valencia I, Roe CR, Pascual JM. Pyruvate carboxylase deficiency: mechanisms, mimics and anaplerosis. Mol Genet Metab 2010;101:9-17
46. Burgess SC, Hausler N, Merritt M, et al. Impaired tricarboxylic acid cycle activity in mouse livers lacking cytosolic phosphoenolpyruvate carboxykinase. J Biol Chem 2004;279:48941-48949
47. Bandsma RH, Wiegman CH, Herling AW, et al. Acute inhibition of glucose- 6-phosphate translocator activity leads to increased de novo lipogenesis and development of hepatic steatosis without affecting VLDL production in rats. Diabetes 2001;50:2591-2597
48. van Poelje PD, Potter SC, Chandramouli VC, Landau BR, Dang Q, Erion MD. Inhibition of fructose 1,6-bisphosphatase reduces excessive endogenous glucose production and attenuates hyperglycemia in Zucker diabetic fatty rats. Diabetes 2006;55:1747-1754
49. Chen JL, Peacock E, Samady W, et al. Physiologic and pharmacologic factors influencing glyceroneogenic contribution to triacylglyceride glycerol measured by mass isotopomer distribution analysis. J Biol Chem 2005; 280:25396-25402
50. Nye CK, Hanson RW, Kalhan SC. Glyceroneogenesis is the dominant pathway for triglyceride glycerol synthesis in vivo in the rat. J Biol Chem 2008;283:27565-27574
51. Millward CA, Desantis D, Hsieh CW, et al. Phosphoenolpyruvate carboxykinase (Pck1) helps regulate the triglyceride/fatty acid cycle and development of insulin resistance in mice. J Lipid Res 2010;51:1452-1463
52. Samuel VT, Liu ZX, Qu X, et al. Mechanism of hepatic insulin resistance in non-alcoholic fatty liver disease. J Biol Chem 2004;279:32345-32353